Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 5,940 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
Interventions
intravenous immune globulin (IVIG)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Livingston, New Jersey • New York, New York
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Utilization of a Videoscope in Periodontal Regeneration

NCT05275192
Conditions
Chronic Periodontitis
Interventions
Videoscope-assisted periodontal regeneration minimally invasive surgery, Periodontal regeneration minimally invasive surgery, Guided tissue regeneration surgery
Device · Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Head and Neck Cancer
Interventions
Celecoxib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

NCT00689052
Conditions
Fibromyalgia
Interventions
pramipexole ER, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions
Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy
Behavioral · Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gingival Recession, Lack of Keratinized Gingiva (Disorder)
Interventions
progenitor potential of Gingival Mesenchymal cells
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Terminated Phase 2 Interventional Results available

Binge Eating & Birth Control

NCT04278755
Conditions
Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions
Drospirenone-Ethinyl Estradiol Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
Conditions
Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more
Conditions
Children, Lacerations, Procedures, Child, Pain
Interventions
hydrocodone/acetaminophen, Sugar water
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
Interventions
Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Dyskinesias, Drug-induced
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more
Conditions
Heart Failure
Interventions
sodium nitrite, Control
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Conditions
Chronic Primary Insomnia
Interventions
ACT-078573 oral capsules at 25 and 100 mg and matching placebo, ACT-078573 and matching placebo
Drug
Lead sponsor
Midnight Pharma, LLC
Industry
Eligibility
65 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 16 more
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Conditions
Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway Glioma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Visual Pathway Glioma
Interventions
Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

NCT04875676
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey